Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

The S&P 500 rallied in the wake of last week's election results, climbing 3.8% since Nov. 5 at Wednesday's prices. But not ...

Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...

(Bloomberg) -- Merck KGaA posted earnings that topped estimates as its ... the company said in the statement. Its health care ...

MERCK lowered the top end of its full-year sales guidance after demand for its HPV vaccine fell for a second straight quarter ...

The September Consumer Price Index data showed ... presenting it as a crucial stakeholder in the animal health industry. On October 1, Merck & Co., Inc. (NYSE:MRK) acquired CN201 from Curon ...

Additionally, the September Consumer Price ... Sharp & Dohme (MSD), Merck is renowned for its work in developing pharmaceuticals, vaccines, biologic therapies, and animal health products.